The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

Lazenby, Michelle, Gilkes, Amanda, Marrin, C., Evans, Anna ORCID: https://orcid.org/0000-0002-2430-811X, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 and Burnett, A. K. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28 , pp. 1953-1959. 10.1038/leu.2014.90

Full text not available from this repository.

Abstract

Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16 and 21%, respectively had an FLT3 and NPM1 mutation. An FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score, the molecular information provided additional prognostic definition in 11% of patients.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Nature Publishing
ISSN:	0887-6924
Date of Acceptance:	11 February 2014
Last Modified:	28 Oct 2022 10:36
URI:	https://orca.cardiff.ac.uk/id/eprint/78972

Citation Data

Cited 50 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item